Immuno-Oncology Europe 2019
27Oct
06Aug
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
30Apr
2019 ASCO Annual Meeting
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...
12Apr
Precision Biologics and NCI investigators to discuss NEO-201 development program at First Internation Congress of Bioimmunotherapy of Cancer
First international congress of
BIOIMMUNOTHERAPY OF CANCER
An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala...
30Mar
AACR Annual Meeting
Mechanisms of action of a neoantigen-targeting antibody NEO-201
AACR Annual Meeting - March 30-April 4 2019...
10Mar
Dr. Philip M Arlen to deliver to presentations on the NEO-201 program at the Molecular Med Tri-Con Meetings, March 10-15th, SF, CA
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen
Philip M. Arlen,...
01Nov
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer
NIH 11/01/2018 Patients...
16Apr
Precision Biologics along with Dr Christina Annunziata, MD, PhD, from the NCI are presenting at the AACR Annual Meeting
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade...
08Jan
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments December 5-7, 2017 in San...
12Oct
Targeting cancer neoantigens: A promising source of immunogens for cancer immunotherapy
Dr. Philip Arlen to Speak at World Vaccine Congress Europe Topic: Targeting cancer neoantigens: A promising source...